[关键词]
[摘要]
目的 研究莫沙必利联合雷贝拉唑钠治疗反流性食管炎的临床疗效。方法 选取2014年7月-2015年12月中山市陈星海医院消化内科收治的反流性食管炎患者60例,随机分为对照组和治疗组,每组各30例。对照组口服雷贝拉唑钠肠溶片,1片/次,1次/d。治疗组在对照组治疗基础上口服枸橼酸莫沙必利胶囊,1粒/次,3次/d。两组均连续治疗8周。观察两组的临床疗效,比较两组症状改善情况和内镜分级情况。比较两组一氧化氮(NO)水平变化和复发情况。结果 治疗后,对照组和治疗组的总有效率分别为70.00%、93.33%,两组比较差异有统计学意义(P<0.05)。治疗后,两组烧心感、反酸、胸骨后灼痛患者例数均显著减少,同组治疗前后差异有统计学意义(P<0.05);且治疗组治疗后这些患者例数少于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组内镜0级人数显著增多,Ⅰ级、Ⅲ级人数显著减少,同组治疗前后差异有统计学意义(P<0.05);治疗后,治疗组内镜0级人数多于对照组,Ⅱ级、Ⅲ级人数少于对照组,两组比较差异有统计学意义(P<0.05)。治疗第4、8周,两组NO水平均较治疗前显著降低,同组治疗前后差异有统计学意义(P<0.05);且治疗后治疗组NO低于对照组,两组比较差异有统计学意义(P<0.05)。对照组和治疗组的复发率分别为36.36%、7.69%,两组比较差异有统计学意义(P<0.05)。结论 莫沙必利联合雷贝拉唑治疗反流性食管炎具有较好的临床疗效,可改善患者的临床症状和内镜分级情况,降低NO水平和复发率,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To analyze the clinical efficacy of mosapride combined with rabeprazole in treatment of reflux esophagitis. Methods Patients (60 cases) with reflux esophagitis in Department of Gastroenterology of Chenxinghai Hospital of Zhongshan City from July 2014 to December 2015 were randomly divided into control and treatment groups, and each group had 30 cases. The patients in the control group were po administered with Rabeprazole Sodium Enteric-coated Tablets, 1 tablet/time, once daily. The patients in the treatment group were po administered with Mosapride Citrate Capsules on the basis of the control group, 1 grain/time, three times daily. The patients in two groups were treated for 8 weeks. After treatment, the efficacy was evaluated, and the changes of symptoms improvement and endoscopic classification in two groups were compared. The levels of NO and recurrence in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 70.00% and 93.33%, respectively, and there were differences between two groups (P<0.05). After treatment, the cases of heartburn, acid reflux, and retrosternal burning pain in two groups were significantly reduced, and the difference was statistically significant in the same group (P<0.05). After treatment, the cases of this kind of patients in the treatment group were less than those in the control group, with significant difference between two groups (P<0.05). After treatment, the number of endoscopy level 0 in two groups significantly were increased, and the number of level I and Ⅲ significantly reduced, and the difference was statistically significant in the same group (P<0.05). After treatment, the number of endoscopy level 0 in the treatment group were more than those in the control group, and endoscopic level I and Ⅲ in the treatment group were less than those in the control group, with significant difference between two groups (P<0.05). After treatment of 4 and 8 weeks, the levels of NO in two groups were significantly reduced, and the difference was statistically significant in the same group (P<0.05). After treatment, the NO in the treatment group was lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, the recurrence rate in the control and treatment groups were 36.36% and 7.69%, respectively, and there were differences between two groups (P<0.05). Conclusion s Mosapride combined with rabeprazole has clinical curative effect in treatment of reflux esophagitis, and can improve the clinical symptoms and endoscopic classification, also can reduce NO and the recurrence rate, which has a certain clinical application value.
[中图分类号]
[基金项目]
中山市医学科研基金项目(2015J179)